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Ethical research must respect the rights of potential participants.  
Critics have questioned whether involving people with serious mental 
illness (SMI) in research exploits a vulnerable population.  When 
addiction further complicates SMI, it becomes vital to demonstrate 
individual rights are respected during clinical trials.  The ability to 
provide informed consent has traditionally been tested in 4 domains (also 
used by U.S. law to assess competency): Understanding of the basic 
facts, appreciation that the facts apply to you, reasoning about the 
information in order to make a decision, and the ability to express a 
choice.  Our new scale, the modified Evaluation to Sign Consent 
(mESC), is an improvement over currently available tools.  It is quick to 
administer, has scoring anchors, uses visual prompts, and evaluates the 4 
domains with a good balance between understanding, appreciation, and 
reasoning (with 8, 7, and 5 items respectively).  Additionally, the mESC 
specifically evaluates therapeutic misconception (the confusion between 
research and clinical care; 3 items).  Therapeutic misconception is 
common in clinical trials throughout medicine and should be corrected 
prior to study enrollment.  Screening with the mESC will enhance 
clinical trials, especially when working with co-occurring addiction and 
SMI.
Abstract
 Project Burden Issues.
1. [A] People in research projects are asked
to do certain activities, like come for extra
visits.  Can you name one or two activities
you would be asked to do if you joined the
project?
 0: Unaware of extra requirements
 1:
 2: Names some requirements but not ones
critical to the project or which pose risk to the
subject
 3:
 4: Fairly clear view of requirements
 After above scoring is complete, show visual aid listing extra activities (like blood draws) the
subject would be expected to participate in if enrolled in this project.
2. [R] Are any of these project activities
different from what you do in your normal
everyday routine?  How?
 0: Does not relate to requirements in a
personal manner/ No opinion
 1:
 2: Some awareness of personal effect/
Opinion but can’t say why
 3:
 4: Realistic view of personal effect/ Opinion
and can give examples of considering extra
burdens
3. [TM]  If you weren’t in a research project,
would you have to do these things?  Are
you doing them for your personal well-
being or as part of the research?
 0:  Yes, for my benefit
 1:
 2:  Yes, for research =or= No, for my benefit
 3:
 4:  No, for research
 Project Withdrawal.
1. [U] Do the research participants have to
remain in the project until the researcher
says they have finished?  Are participants
allowed to leave the project before it is
finished?  How should they do that?
 0: Cannot quit
 1:
 2: Can quit but not sure how to do it
 3:
 4: Clear on right to withdraw
2. [A] If you join the project but you decide to
pull out before it is finished, can you go
back to your regular treatment?
 0: Can not quit; cannot receive regular
treatment if quit
 1:
 2: Realizes he/she can quit, but unsure how
that affects treatment
 3:
 4: Acknowledges right to quit and still receive
treatment
After above scoring is complete, show visual aid listing: sypmtoms getting worse, side-effects
are uncomfortable, too much time in testing.
3. [R] [Showing visual aid] These are some
reasons why people leave research
projects before the projects are finished.
Would these things make you want to
leave the project?  What else might make
you want to leave the project?
 0: Denies possibility of any adverse effect
which would cause him/her to withdraw
 1:
 2: Vague thoughts about things that would
lead to withdrawal
 3:
 4: Notes specific things that would make
him/her uncomfortable continuing in the
project
 Assignment of medication during research participation.
1. [U] What is being studied in this research
project?
(If patient responds “schizophrenia” ask,
“What is it about schizophrenia that we/the
researchers are trying to figure out?”)
 0: Does not know
 1:
 2: Some reference to schizophrenia treatment
 3:
 4: Clear knowledge that drug treatment is
being studied
2. [U] What problems or symptoms is the
project medication designed to help?
 0: Does not know
 1:
 2: Some reference to relevant symptoms
 3:
 4: Clear knowledge of key symptoms
3. [A] Do you have any of these symptoms?
(Briefly state key symptoms)
 0: Does not admit to having the symptoms or
problems
 1:
 2: States only that the doctors think he/she
has the symptoms
 3:
 4: States has key symptom or problem
4. [A] Do you think the project medication
could affect your symptoms?  How?
 0: No
 1:
 2: Maybe; unsure
 3:
 4: Believes the treatment could affect his/her
symptoms
5. [U] In this research project, what is/are the
experimental medication(s) being studied?
What is a placebo or “sugar pill”?  Could
you get a placebo?
 0: Does not know
 1:
 2: Knows about only treatment OR placebo,
not both
 3:
 4: Specifies experimental drug and placebo as
possible treatments
6. [A] If you join the project, will you get to
choose the project medication you think is






7. [TM] Will your doctor or therapist be able
to make sure you get the project
medication instead of placebo?





8. [U] How do the researchers know which
medication to give to the people in the
project?
 0: Subject does not know; “the one that works
best”
 1:
 2: Research team decides
 3:
 4: Acknowledges random assignment
9.  [TM] (Clarify random assignment if
necessary.)  Is that how your doctor
usually decides which medications you
need most?  How is it different?
 0: Decision made in the same way; don’t know
if same or different
 1:
 2: Knows it is different, but vague about how
 3:
 4: Clear about the difference
 Risks and Benefits.
1. [U] What good things might happen to
patients who join this project?
 0: No benefit for participants; guaranteed
clinical improvement
 1:
 2: Sees potential benefits, but overestimates
potential for subjects to benefit
 3:
 4: Realistic understanding of benefits (does
not need to mention “closer monitoring” as
benefit)
2. [A] How likely is it that good things will
happen to you if you join this project?
 0: Guaranteed
 1:
 2: Unrealistic Expectations
 3:
 4: Realistic; Chance
3. [R] How could those good things make it
easier for you to do the things you like to
do?
 0: No concept of how life would be affected
 1:
 2: Knows it would help but unsure exactly how
 3:
 4: Can point to specific activities that could be
improved
4. [U] What problems might people have
because of joining this project?
(If the patient only mentions side-effects, and
there are other risks [like medication wash-
out], prompt him/her with “What are problems
people might have other than side-effects?”)
 0: Denies risk
 1:
 2: Partially understands risks
 3:
 4: Clear understanding of primary risks (i.e.
medication wash-out, placebo, ineffective
project medication, side-effects- as
appropriate)
After above scoring is complete, show visual aid listing important side-effects and other risks
related to the project [including medication wash-out, placebo etc. as appropriate].
5. [A] These are some things that might be a
problem for people who join the project.  If
you join the project, do you think any of
these could happen to you?
 0: No
 1:
 2: Admits some risks but minimizes possibility
unrealistically
 3:
 4: Acknowledges all are possible
6. [R] How could those experiences make it
harder for you to do the things you like to
do?
 0: No concept of how life would be affected
 1:
 2: Knows it would interfere but unsure exactly
how
 3:
 4: Can point to specific activities that could be
hindered
7.  [U] Will this research benefit people in the
future? How?
 0: No benefit to others; Don’t know
 1:
 2: Acknowledges gain in information but not
sure how that is beneficial
 3:
 4: Acknowledges that new treatment
information can help future patients
8. [R] How do you decide whether to join a
      research project or not?
 0: Doesn’t know; doesn’t think about those
things
 1:
 2:Some appreciation of areas reviewed
 3:
 4: Weighs risks and benefits (Does not need
to say that is what he/she does if it is obvious
from patient that is what is happening)
The modified Evaluation to Sign Consent (mESC):
This first question is not scored and is 
designed to determine if the individual 
can express a choice (One of the four 
domains assessing legal competency in 
the United States).
There is a hierarchy of domains in the instrument with 
Understanding required for some Appreciation 
questions and Appreciation required for some 
Reasoning questions.  
The questions are labeled as to the most complex 
domain they address:
[U] Understanding (8 items)
[A] Appreciation (7 items)
[R] Reasoning (5 items)
[TM] Therapeutic Misconception (3 items)
The questions elicit 
free-response answers, 
but there are anchors 
giving guidance in 
scoring.
There are three visual aids in the 
instrument.  These allow 
individuals to think about study-
related facts without having to 
simultaneously hold them in their 
working memory.
The questions, visual aids, and 
anchors can easily be modified 
for specific trials.
Determine if the potential subject is able to
communicate and maintain a meaningful
conversation, and if the patient is willing to
discuss the research project.
 If YES, proceed
 
 If NO, consent cannot be validated at this time
The Instrument is divided into four sections to 







•Popular assessment tools for informed consent in research include the 
original Evaluation to Sign Consent (ESC) & MacArthur Competency 
Assessment Tool for Clinical Research (MacCAT-CR).
•The ESC is a 6-item free-response test of understanding.
•MacCAT-CR is a 20-item manualized interview requiring training,  








Advantages of the mESC
•Quick to administer (Average time in preliminary study was about 16 minutes, n=18).
•Visual cues eliminate the need to hold facts in working memory while simultaneously thinking about them.
•More balanced testing of Understanding, Appreciation, and Reasoning.
•Addition of Therapeutic Misconception as a separate, scored domain.
•Anchors give guidance in scoring.
•Versatile- easily modified to a wide-range of clinical studies. 
•Can be used to test interventions designed to enhance informed consent.
•Can be used to track degradation of elements of consent over long clinical trials.
